PHS
VIR icon

Pekin Hardy Strauss’s Vir Biotechnology VIR Stock Holding History

Pekin Hardy Strauss’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,500
Closed -$500K – 360
2021
Q3 		$500K Buy
+11,500
New +$498K 0.07% 217

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Pekin Hardy Strauss's VIR Position: Q4 2021 in Review

Pekin Hardy Strauss sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 11,500 shares — an estimated $500K sold.

Pekin Hardy Strauss first reported a position in VIR in Q3 2021 and held it in 1 quarter. The position peaked at $500K in Q3 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

  • Pekin Hardy Strauss reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Pekin Hardy Strauss sold 11,500 Vir Biotechnology shares in Q4 2021, an estimated $500K.
  • Pekin Hardy Strauss first reported a position in Vir Biotechnology in Q3 2021 and held it in 1 quarter.
  • Pekin Hardy Strauss's Vir Biotechnology position peaked at $500K in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on Pekin Hardy Strauss's 13F filing for Q4 2021, filed 8 Feb 2022.